Track topics on Twitter Track topics that are important to you
Miraca Holdings’ Fujirebio Inc. licensed Janssen Pharmaceuticals Inc. rights to develop and commercialize an amyloid beta 42/40 ratio assay that will run on Fujirebio’s Lumipulse chemiluminescent ...
MALVERN, Pa.–(BUSINESS WIRE)–Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fuji...
Fujirebio Diagnostics, a consolidated subsidiary of Miraca Holdings, has secured approval from the US Food and Drug Administration (FDA) for its Lumipulse G B•R•A•H•M•S procalcitonin (PCT) a...
Miraca’s consolidated subsidiary Fujirebio has signed an agreement with US-based Janssen Pharmaceuticals for the development and commercialization of an AMYLOID β 42/40 RATIO assay.
Fujirebio Inc., a consolidated subsidiary of Miraca Holdings Inc., (Head office: Shinjuku-ku, Tokyo, President and CEO: Yoshihiro Ashihara, hereinafter “Fujirebio” or “the C...
Testing for Change in PCT Levels Assists with Antibiotic Stewardship and Risk Assessment Of Lower Respiratory Tract Infections and Sepsis Fujirebio Diagnostics, Inc., a...
SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...
SummaryMarket Segment as follows:By Region AsiaPacific Segment by Company, Type and Application North America Segment by Company, Type and Application Europe Segment by Company, Type and Appl...
Founded in 1950, Fujirebio Inc. is an international leading diagnostic supplier, a part of Miraca Group, Japanâs leading healthcare group with its focus on clinical laborator...
Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pi...
Formerly Certocor Diagnostics,Fujirebio Diagnostics,Inc.was acquired by ourparent company Fujirebio,Inc.of Tokyo,Japan in November 1998.
Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and co...
Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, ...
We have published hundreds of Fujirebio Inc. news stories on BioPortfolio along with dozens of Fujirebio Inc. Clinical Trials and PubMed Articles about Fujirebio Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Fujirebio Inc. Companies in our database. You can also find out about relevant Fujirebio Inc. Drugs and Medications on this site too.
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...